Tag: NASD:POAI

As of the most recent check today, Predictive Oncology Inc. (NASDAQ: POAI) shares were significantly rising 69.58% to $1.89. A notable advancement in creating a new compound in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan drove that momentum.

A Successful Collaboration with the University of Michigan

Predictive Oncology has partnered with the NPDC at the Life Sciences Institute at the University of Michigan to advance drug discovery. Applying Predictive’s state-of-the-art machine learning technology, which has proven successful in predicting the efficacy of possible drugs, is the main goal of the collaboration. To expedite the screening procedure and improve the likelihood of success, this platform makes use of a sizable biobank of live-cell tumor samples.

Novel Approaches to Cancer Treatment Using Natural Products

The NPDC has one of the largest natural products libraries in the United States, including specimens from biodiversity hotspots across the globe. Numerous authorized small-molecule medications have been generated from natural chemicals, which have historically played a significant role in drug development.

Three of the 21 new chemicals that Predictive Oncology evaluated showed consistently robust anti-tumor responses across a variety of cancer types, surpassing the effectiveness of the well-known chemotherapeutic medication doxorubicin.

Machine Learning to Speed Up Drug Discovery

Promising results were obtained by evaluating these chemicals on models of ovarian, colon, and breast cancer. Using only 7% of the potential wet lab experiments, POAI’s machine learning model successfully predicted outcomes for 73% of all possible tests. This significant reduction in experimental time could potentially eliminate up to two years of traditional lab testing.

Future Prospects and Further Investigations

By examining only 1% of the NPDC’s accessible chemicals, the partnership produced encouraging results that open the door for more research. The NPDC anticipates growing their collaboration with Predictive Oncology (POAI), investigating other substances, and disseminating the results of these continuing investigations.

After announcing a strategic expansion, Predictive Oncology Inc. (NASDAQ: POAI) has seen its shares gain significant momentum during the current market session. As of the latest check, POAI stock has surged by 109.35%, trading at $2.24 on the US stock charts.

Predictive Oncology Expanding Through AI/ML Driven Drug Discovery Platform

With the intention of finding novel biomarkers that can predict patient outcomes and treatment responses in cancer, Predictive Oncology has disclosed its ambitions to improve its AI/ML-driven drug development platform. In partnership with UPMC Magee-Womens Hospital, a retrospective investigation on ovarian cancer produced findings that served as inspiration for this biomarker identification project.

The results were showcased at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). Compared to clinical data alone, Predictive Oncology’s multi-omic machine learning models in the research were able to accurately identify critical traits and predict both short-term (two-year) and long-term (five-year) survival outcomes for patients with ovarian cancer.

Advancements and Broader Applicability

Predictive Oncology has conducted research and collected and evaluated data to facilitate the identification and creation of new biomarkers for ovarian cancer. We will investigate these indicators further, both on our own and in conjunction with biopharma businesses. The business has previously shown the effectiveness of its machine learning platform by using a variety of patient samples from biobanks to accurately predict medication reactions.

POAI is now advancing this process by applying state-of-the-art deep learning techniques for biomarker discovery related to patient overall survival (OS) and drug response. This platform enables the application of deep learning to appropriate patient cohorts, accelerating the initial stages of biomarker discovery.

The identification of novel cancer biomarkers presents a significant opportunity for Predictive Oncology’s platform, leveraging the extensive value of its diverse patient samples and data. This also opens potential new revenue streams for the company.

Market Potential

Predictive Oncology’s technology holds broad applicability, including the development of clinical decision support tools for clinical trial screening and informing drug discovery and development. These capabilities extend beyond ovarian cancer, potentially aiding in the discovery of biomarkers for other cancer types.